Vertex Transferred Drug and study Sponsorship to Merck Sept 2017 An Open-Label, First-in-Human Study of the Safety, Tolerability &Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors: Part C3 (SCLC)
|Effective start/end date||7/15/16 → 6/30/20|
- Vertex Pharmaceuticals Incorporated
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.